First in human study to evaluate the safety, tolerabilityand preliminary efficacy of the bispecific PSMAxCD3antibody CC-1 in patients with castration resistantprostate carcinoma
Phase 1
Recruiting
- Conditions
- Prostate CancerMedDRA version: 20.0Level: LLTClassification code: 10036910Term: Prostate cancer NOS Class: 10029104Therapeutic area: Diseases [C] - Male Urogenital Diseases [C12]
- Registration Number
- CTIS2024-512894-29-00
- Lead Sponsor
- niversitaetsklinikum Tuebingen AöR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 44
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method